June 10, 2009
By:Maude L. Campbell
Intensive lowering of blood glucose to a hemoglobin A1c (HbA1c) level under 6% is not associated with the increased mortality that caused an early halt to the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial last year. The increased mortality also does not appear to be related to increased hypoglycemic episodes among those receiving intensive treatment.
 |
June 10, 2009
By:Wayne Kuznar
Although bariatric surgery is becoming an increasingly accepted option to reverse type 2 diabetes, lifestyle interventions, including smoking cessation, improved nutrition, and increased physical activity, coupled with appropriate pharmacotherapy, remain the mainstays for the management of type 2 diabetes.
|
June 10, 2009
By:Maude L. Campbell
Patients treated early after a type 2 diabetes diagnosis, those with elevated high-density lipoprotein (HDL) levels, and those without a history of severe hypoglycemic episodes are most likely to benefit from intensive glucose control, according to subanalyses of data from the VA Trial of Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT).
|
June 10, 2009
By:Maude L. Campbell
Fenofibrate therapy lowers the incidence of cardiovascular disease in women more so than in men, according to results of the Fenofibrate and Event Lowering in Diabetes (FIELD) study.
|
June 10, 2009
By:Maude L. Campbell
A telephone-intervention program significantly improved oral diabetes medication adherence compared to printed patient education materials, reports Hillel W. Cohen, MD, department of epidemiology and population health, Albert Einstein College of Medicine, Bronx, NY. The improvement in medication possession ratio is associated with a decline in HbA1c, according to Dr. Cohen. A significant effect was not observed on insulin regimen adherence.
|
June 10, 2009
By:Wayne Kuznar
A small clinical study shows improvements in insulin secretion and insulin sensitivity and prevention of oxidative stress with the use of alpha-lipoic acid in obese persons with impaired glucose tolerance (IGT), according to Chinese researchers.
|
June 9, 2009
By:Maude L. Campbell
A significantly greater proportion of patients with type 2 diabetes with mixed dyslipidemia treated with a combination of fenofibric acid and rosuvastatin achieved American Diabetes Association (ADA) target lipid levels compared to those taking rosuvastatin alone, reports Robert S. Rosenson, MD, State University of New York, Brooklyn, NY. "Because diabetes is a risk factor for heart disease, it is particularly important that patients with diabetes and mixed dyslipidemia manage all three key lipid parameters," he says.
|
June 9, 2009
By:Wayne Kuznar
Metabolic changes occur well before an actual diagnosis of type 2 diabetes, providing opportunities for screening and prevention, say British researchers. Results of the WHITEHALL II study suggest both insulin resistance and beta-cell dysfunction are likely present years before a diabetes diagnosis.
|
June 9, 2009
By:Wayne Kuznar
Inhibitors of sodium glucose cotransporter (SGLT)-2 offer the promise of reducing fasting glucose and hemoglobin A1c (HbA1c) levels, independent of acting on insulin, while reducing weight, says John P. Wilding, DM. Several SGLT-2 inhibitors are in development, and one, dapagliflozin, is in phase 3 clinical studies.
|
| 
